Press release
Strong Growth Ahead: Gastroesophageal Reflux Disease Therapeutics Market Size To Grow At Arecord 6.5% Cagr By 2029
Gastroesophageal Reflux Disease Therapeutics
How Big Is the Gastroesophageal Reflux Disease Therapeutics Market Size Expected to Be by 2034?
The market size for therapeutics for gastroesophageal reflux disease has been consistently expanding over the past few years. The market value is predicted to escalate from $5.93 billion in 2024 to $6.14 billion in 2025, with a compound annual growth rate (CAGR) of 3.6%. Various factors have driven this growth in the past, including evolving lifestyles and food habits, an aging demographic, heightened attention and diagnosis, prevalent stress-filled lifestyles, and an upward trend in obesity rates.
Steady expansion is expected in the therapeutics market for gastroesophageal reflux disease over the upcoming years. The market size is projected to increase to $7.89 billion in 2029, with a compound annual growth rate (CAGR) of 6.5%. Growth within the predicted period could be a result of increasing demand for innovative therapies, a rising elderly population, personalized treatment strategies, a shift towards non-drug interventions, and the introduction of biologics and novel therapies. The forecast period may witness other notable trends such as the advocacy of alternative treatments and mind-body practices, intensified research into gut health, the creation of patient-focused care models, particular marketing efforts for gerd awareness, and the incorporation of digital health technologies.
Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12058
What Are the Emerging Segments Within the Gastroesophageal Reflux Disease Therapeutics Market?
The gastroesophageal reflux disease therapeutics market covered in this report is segmented -
1) By Type: Branded, Generic
2) By Drug Class: Antacids, Proton Pump Inhibitors, Histamine Blockers, Pro-Kinetic Agents, Other Drugs Class
3) By Distribution Channel: Hospital Pharmacy, Drug Stores, General Stores, Super markets
4) By Application: Crohn's Disease, Gastroesophageal Reflux Disease (GERD), Ulcerative Colitis
Subsegments:
1) By Branded: Proton Pump Inhibitors (PPIs), H2-Receptor Antagonists, Antacids, Coating Agents
2) By Generic: Generic Proton Pump Inhibitors (PPIs), Generic H2-Receptor Antagonists, Generic Antacids, Generic Coating Agents
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12058&type=smp
What Long-Term Drivers Are Shaping Gastroesophageal Reflux Disease Therapeutics Market Trends?
The projected rise in gastroesophageal reflux disease (GERD) instances is predicted to expedite the expansion of the GERD therapeutics market. GERD, a chronic disorder marked by stomach acid flowing back into the esophagus, results in symptoms like heartburn and regurgitation, and might lead to complications. The therapeutics designed for GERD assist in alleviating and managing acid reflux symptoms by balancing the gut pH, managing inflammation, and enhancing the esophageal function. For example, a WebMed article published in September 2022 indicated that over 60 million American adults experience heartburn once a month at least, and above 15 million endure it daily. Additionally, the National Library of Medicine, an American federal medical library, disclosed in July 2022 that GERD is a frequently diagnosed digestive disease in the U.S. with a 20% prevalence, leading to a substantial economic load due to direct and indirect costs and negatively affecting the quality of life. Hence, the increased prevalence of GERD is likely to stimulate the growth of the gastroesophageal reflux disease therapeutics market.
Who Are the Top Competitors in Key Gastroesophageal Reflux Disease Therapeutics Market Segments?
Major companies operating in the gastroesophageal reflux disease therapeutics market include Pfizer Inc., Johnson and Johnson, Novartis AG, Sanofi S.A., AstraZeneca plc, Medtronic PLC, GlaxoSmithKline plc, Eisai Co. Ltd., Takeda Pharmaceutical Company Limited, bioMerieux SA, Teva Pharmaceutical Industries, Dr. Reddy's Laboratories Ltd., Amneal Pharmaceuticals LLC, CHEPLAPHARM Arzneimittel GmbH, Daewoong Pharmaceutical Co. Ltd, Ironwood Pharmaceuticals Inc., Sebela Pharmaceuticals Inc., Camber Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., EndoGastric Solutions, RaQualia Pharma Inc, TWi Pharmaceuticals Inc., Astellas Pharma Inc., SFJ Pharmaceuticals Group, Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Limited
What Gastroesophageal Reflux Disease Therapeutics Market Trends Are Gaining Traction Across Different Segments?
A crucial trend that is gaining momentum in the gastroesophageal reflux disease therapeutics market is product innovation. To maintain their competitive edge, leading businesses in this market are focusing on the development of innovative drugs. For instance, Phathom Pharmaceuticals, a US-based biopharmaceutical corporation, in November 2023, introduced VOQUEZNA (vonoprazan), a potassium-competitive acid blocker cleared for the treatment and maintenance of all erosive esophagitis grades, and for providing relief from heartburn linked to both erosive and non-erosive GERD. Impressive results were observed during the clinical trials, with a favorable healing rate of 93% in patients taking the 20 mg dosage, surpassing the 85% achieved with the regular proton pump inhibitor (PPI) lansoprazole.
Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/gastroesophageal-reflux-disease-therapeutics-global-market-report
Which Regions Are Becoming Hubs for Gastroesophageal Reflux Disease Therapeutics Market Innovation?
North America was the largest region in the gastroesophageal reflux disease therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroesophageal reflux disease therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Gastroesophageal Reflux Disease Therapeutics Market?
2. What is the CAGR expected in the Gastroesophageal Reflux Disease Therapeutics Market?
3. What Are the Key Innovations Transforming the Gastroesophageal Reflux Disease Therapeutics Industry?
4. Which Region Is Leading the Gastroesophageal Reflux Disease Therapeutics Market?
Why This Report Matters:
Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.
Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.
Efficient Research: Quickly identify market growth, leading players, and major segments.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Strong Growth Ahead: Gastroesophageal Reflux Disease Therapeutics Market Size To Grow At Arecord 6.5% Cagr By 2029 here
News-ID: 3997103 • Views: …
More Releases from The Business Research Company
Company Registration Service Market Landscape 2025: Forecast Data and Growth Str …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Company Registration Service Market Through 2025?
The market size for company registration services has seen robust growth in the recent past. The market is projected to expand from $10.67 billion in 2024 to $11.55 billion in 2025, exhibiting a compound annual growth…
Comprehensive 2025 Commercial Toilet Partition Market Overview: Trends, Forecast …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Commercial Toilet Partition Market Through 2025?
In recent years, the market size for commercial toilet partitions has significantly expanded. The forecast predicts a rise from $1.82 billion in 2024 to $1.95 billion in 2025, with a compound annual growth rate (CAGR) of…
Key Trends Influencing the Growth of the Commercial Insurance For Small And Medi …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Commercial Insurance For Small And Medium-Sized Enterprises (SMEs) Market Through 2025?
The market size of commercial insurance for small and medium-sized enterprises (SMEs) has seen substantial growth over the recent years. A rise from $111.83 billion in 2024 to $119.76 billion in…
Growing Focus On Reducing Greenhouse Gas Emissions Driving The Market Growth Due …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Combustion Emissions Analyzer Market Through 2025?
In the past few years, the market size for combustion emissions analyzer has seen robust growth. It is projected to increase from $1.02 billion in 2024 to $1.09 billion in 2025, with a compound annual growth…
More Releases for Disease
Protheragen Announces Disease Model Development Services to Enhance Rare Disease …
Protheragen announced the release of its disease model development services provided to enhance rare disease research. With an increasing focus on rare diseases and the need for tailored research models, Protheragen is dedicated to providing cutting-edge solutions to support this important area of medical research.
Rare diseases, which affect a small percentage of the population, pose unique challenges for researchers due to their limited understanding and lack of available treatment options.…
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the…
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol…
Moyamoya Disease Market - A Scientometric Assessment of Disease During 2018-23
Market Highlight:
Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and…
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene…
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and…
